



## **Zentalis Pharmaceuticals to Participate in the Webbush PacGrow Healthcare Conference**

August 3, 2022

NEW YORK and SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a panel discussion entitled "Bullseye – Targeted Oncology – Quanta of Targets" at the Webbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 10:20 a.m. ET.

A live webcast will be accessible through the Investors section of the Company's website at [www.zentalis.com](http://www.zentalis.com). Following the event, an archived webcast will be available on the Zentalis website.

### **About Zentalis Pharmaceuticals**

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an epidermal growth factor receptor (EGFR) inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, Ltd., to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.

For more information, please visit [www.zentalis.com](http://www.zentalis.com). Follow Zentalis on Twitter at [@ZentalisP](https://twitter.com/ZentalisP) and on LinkedIn at [www.linkedin.com/company/zentalis-pharmaceuticals](https://www.linkedin.com/company/zentalis-pharmaceuticals).

### **Investor Contact:**

Alexandra Roy  
Solebury Trout  
[aroy@soleburytrout.com](mailto:aroy@soleburytrout.com)

### **Media Contact:**

Julia Deutsch  
Solebury Trout  
[jdeutsch@soleburytrout.com](mailto:jdeutsch@soleburytrout.com)